Page 28
Large diagnostics companies likely to remain major players with increasing role for companies that can offer combination of tests
Key players offer a multitude of multiparametric tests Major test developers including Roche Diagnostics , Abbott Laboratories , Agilent Technologies , Qiagen , Thermo Fisher Scientific and Myriad Genetics are expected to continue to be major developers of CDx . While the increasing complexity of the analysis and the heterogeneity of the tests may see an increasing role for service providers able to provide both testing and analytical services , there should be an increasing role for point-of-care diagnostic platforms in routine treatment monitoring or in territories where central laboratory testing is limited . Smaller companies can focus on niche diagnostic technologies and earn the attention of these larger players in early clinical trial stages .
Diverse portfolio the end goal The ability to test for a variety of markers is an advantage and therefore it is likely companies that have multiple CDx tests will consolidate their position . As the number of CDx tests increase to a point where there are multiple drugs indicated for the same pathology with different markers , being able to test for all of these in one test is essential . This is where Foundation medicine and Dako ( Agilent ) are strongest and likely to continue their strong market position .
Table 15 : Selected CDx players
Source : goetzpartners Research , FactSet
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .